Anatara Lifesciences is developing non-antibiotic oral solutions for gastrointestinal diseases in animals and humans. Our lead product Detach™ is a natural product that will help address global concerns around the overuse of antibiotics in animals and their feed that is contributing to the rise of so-called “super bugs” that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.
Latest news All news
Wilson HTM has released its latest research and valuation report on Anatara Lifesciences (ANR). The report maintained a Speculative BUY rating and a new price target of $1.75 per share.
Please open the attached PDF to view the report.
Anatara Lifesciences released an Appendix 3Y – Change of Director’s Interest Notice, to the ASX on 27th April 2016.
Please click here to view the ASX announcement.